Orchid Pharma aims to launch its new drug, Enmetazobactum, by next quarter. Enmetazobactum was discovered by Orchid in 2008, when the company was under the previous management. Since the drug has been approved by the US, the DCGI has exempted Orchid from the need to do clinical trials in India. “With this approval, Orchid Pharma intends to improve the treatment landscape for serious infections in India, providing patients with access to advanced and effective therapy options,” the release said. On the BSE today, shares of the Rs 819-crore Orchid Pharma closed at ₹1,045.15, which was ₹1.7 (0.16 per cent) lower than the previous close.

Source: The Hindu June 14, 2024 01:31 UTC